EUS (Endoultrasonography)

What is an endoscopic ultrasound?

A flexible endoscope carries an ultrasound transducer through the mouth into the stomach and duodenum (or, for rectal indications, from below). From inside, the probe images adjacent anatomy with a clarity distance cannot match: the pancreas in its entirety, the bile duct and gallbladder, the gut wall’s five distinct layers, nearby lymph nodes and vessels. When something needs proof rather than description, EUS-guided fine-needle aspiration or biopsy (FNA/FNB) samples it under continuous ultrasound vision — the standard route to a tissue diagnosis of pancreatic masses without surgery.

What EUS is used for

The classic indications: evaluating pancreatic masses and cysts — where EUS both characterises and biopsies; hunting small bile-duct stones that other imaging equivocates on; staging how deeply an oesophageal, gastric or rectal tumour has grown through the wall and whether nearby nodes are suspicious — depth-staging is EUS home ground; clarifying submucosal bumps seen at routine endoscopy, which layer they arise from and what they likely are; and assessing chronic pancreatitis. On the therapeutic side, EUS increasingly acts as well as looks: draining pancreatic fluid collections and guiding nerve-block procedures such as coeliac plexus block for pancreatic pain.

The procedure: what to expect

EUS is performed under sedation — most patients sleep through it — after a fasting period your instructions specify. The examination itself typically takes twenty to sixty minutes depending on whether sampling or a therapeutic step is included. Afterwards: an hour or two of recovery while sedation wears off, a companion to accompany you home, no driving that day, and at most a mild sore throat or bloating. If biopsy was taken, pathology results follow within days and are read into the plan — at Acibadem, into a tumour board where the finding warrants one.

EUS vs CT, MRI and ERCP

CT and MRI/MRCP map the region and remain the first pictures in most pathways; EUS adds near-field resolution — the small lesion, the wall layer, the equivocal node — plus the needle that turns an image into a diagnosis. Against ERCP, the division of labour is clean: ERCP is a treatment tool for the bile duct (removing stones, placing stents) with real procedural risks; EUS is the low-risk way to look and decide whether ERCP is needed at all. Modern units run them as a tandem, sometimes in one sedation.

Honest risks

Diagnostic EUS is a low-risk procedure; sampling adds small risks — bleeding, infection, and uncommonly pancreatitis after pancreatic puncture — quantified for your case beforehand. Perforation is rare. The sedation itself is screened and monitored by anaesthesia protocols; tell the team about heart or lung conditions and blood thinners early, since they shape the plan rather than cancel it.

EUS at Acibadem

EUS runs within the group’s gastroenterology practice, with corporate-verified endosonography capability at campuses including City Clinic Tokuda in Sofia, Mladost’s diagnostic floors and the Varna medical centre — with pathology through the group’s ISO-accredited laboratories and findings that need oncology read directly into tumour boards. Records-first applies: prior imaging travels ahead, so the examination answers a defined question rather than starting from zero.

Pancreatic cysts: EUS’s most consequential clinic

Modern scanning finds pancreatic cysts constantly — most incidental, most harmless, a minority carrying real malignant potential — and sorting them is where EUS earns its keep. Near-field imaging reads the features that matter: septations, wall thickening, mural nodules, duct communication and calibre. Fluid aspirated through the needle speaks its own dialect: CEA levels and molecular markers separating mucinous cysts (the surveillance-or-surgery family) from serous ones (the reassurance family), amylase hinting at pseudocysts after pancreatitis. The output is a disposition, not a shrug: discharge with reassurance, a defined surveillance interval by size and features, or referral to surgery when worrisome features stack up. For a patient carrying an “incidental cyst” sentence on a scan report, this examination is usually the difference between years of vague worry and a plan with dates on it.

Therapeutic EUS: when the needle becomes the treatment

The same access that samples can treat, and interventional EUS has grown into a discipline of its own. Established territory: draining pancreatic fluid collections and walled-off necrosis through the stomach wall with stents — replacing operations that once dominated severe pancreatitis care; coeliac plexus block and neurolysis, delivering pain control to the nerve bundle behind the pancreas for cancer pain that medication ceilings cannot reach; and pseudocyst management on the same logic. The expanding frontier — EUS-guided bile-duct and gallbladder drainage where ERCP’s route is blocked — belongs to high-volume centres and honest case selection. Each of these carries its own risk-benefit conversation, held with the team that also offers the alternatives; interventional EUS at its best is exactly that — an alternative offered, not an inevitability sold.